CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

Current stock price

18.49 CAD
+0.24 (+1.32%)
Last:

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • CPH had positive earnings in the past year.
  • CPH had a positive operating cash flow in the past year.
  • Of the past 5 years CPH 4 years were profitable.
  • CPH had a positive operating cash flow in 4 of the past 5 years.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of CPH (11.77%) is better than 90.32% of its industry peers.
  • Looking at the Return On Equity, with a value of 15.23%, CPH belongs to the top of the industry, outperforming 87.10% of the companies in the same industry.
  • CPH has a Return On Invested Capital of 7.23%. This is amongst the best in the industry. CPH outperforms 87.10% of its industry peers.
  • CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 8.64%.
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROIC 7.23%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • CPH has a Profit Margin of 34.68%. This is amongst the best in the industry. CPH outperforms 100.00% of its industry peers.
  • In the last couple of years the Profit Margin of CPH has grown nicely.
  • CPH has a better Operating Margin (25.51%) than 83.87% of its industry peers.
  • CPH's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 74.32%, CPH belongs to the top of the industry, outperforming 93.55% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CPH has declined.
Industry RankSector Rank
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CPH.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CPH is destroying value.
  • CPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 7.61 indicates that CPH is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CPH (7.61) is better than 96.77% of its industry peers.
  • CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
  • The Debt to FCF ratio of CPH (0.45) is better than 96.77% of its industry peers.
  • CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • CPH's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CPH outperforms 67.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Altman-Z 7.61
ROIC/WACC0.84
WACC8.59%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
  • CPH's Current ratio of 1.30 is on the low side compared to the rest of the industry. CPH is outperformed by 70.97% of its industry peers.
  • CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CPH has a Quick ratio of 0.98. This is in the lower half of the industry: CPH underperforms 64.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.98
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CPH.CA Growth Analysis

3.1 Past

  • CPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 126.09%, which is quite impressive.
  • CPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 43.65% yearly.
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.30% on average over the next years.
  • Based on estimates for the next years, CPH will show a quite strong growth in Revenue. The Revenue will grow by 11.81% on average per year.
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • CPH is valuated correctly with a Price/Earnings ratio of 13.02.
  • Compared to the rest of the industry, the Price/Earnings ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 77.42% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of CPH to the average of the S&P500 Index (27.95), we can say CPH is valued rather cheaply.
  • CPH is valuated rather expensively with a Price/Forward Earnings ratio of 17.94.
  • 64.52% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 38.68. CPH is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 13.02
Fwd PE 17.94
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH is on the same level as its industry peers.
  • CPH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CPH is cheaper than 74.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.41
EV/EBITDA 17.57
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The decent profitability rating of CPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.3
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • CPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (4/20/2026, 7:00:00 PM)

18.49

+0.24 (+1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.97%
Ins Owner ChangeN/A
Market Cap467.43M
Revenue(TTM)N/A
Net Income(TTM)17.36M
Analysts77.5
Price Target19.92 (7.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)1.74%
PT rev (3m)1.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE 13.02
Fwd PE 17.94
P/S 6.82
P/FCF 11.41
P/OCF 11.38
P/B 3
P/tB 14.94
EV/EBITDA 17.57
EPS(TTM)1.42
EY7.68%
EPS(NY)1.03
Fwd EY5.57%
FCF(TTM)1.62
FCFY8.76%
OCF(TTM)1.63
OCFY8.79%
SpS2.71
BVpS6.17
TBVpS1.24
PEG (NY)N/A
PEG (5Y)0.3
Graham Number14.0429 (-24.05%)
Profitability
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROCE 10.05%
ROIC 7.23%
ROICexc 7.75%
ROICexgc 33.36%
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
FCFM 59.76%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Debt/EBITDA 0.67
Cap/Depr 1.2%
Cap/Sales 0.17%
Interest Coverage 250
Cash Conversion 152.24%
Profit Quality 172.34%
Current Ratio 1.3
Quick Ratio 0.98
Altman-Z 7.61
F-Score7
WACC8.59%
ROIC/WACC0.84
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year143.38%
EBIT Next 3Y49.37%
EBIT Next 5Y35.85%
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%

CIPHER PHARMACEUTICALS INC / CPH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CPH.CA.


Can you provide the valuation status for CIPHER PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for CIPHER PHARMACEUTICALS INC?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 7 / 10.


What is the earnings growth outlook for CIPHER PHARMACEUTICALS INC?

The Earnings per Share (EPS) of CIPHER PHARMACEUTICALS INC (CPH.CA) is expected to decline by -27.65% in the next year.